I recently interviewed Dr. John Hubbard, sr. VP and worldwide head of development operations for Pfizer (NYSE: PFE). One of his current favorite subjects is disruptive innovation. I have heard this buzzword a lot lately. Being that Hubbard manages more than 700 clinical development projects for Pfizer, I thought it was time to learn more about the origin of this concept and what it means for the future of drug development.
Founded On Research That...'Brought The House Down'
For Epizyme, a Cambridge, MA-based biopharma company established almost three years ago, 2011 is already a good year. In early January, the company announced it had forged a global R&D alliance with GlaxoSmithKline (GSK) to develop novel small molecule, epigenetics-based therapeutics against cancer and other diseases.
PAREXEL PACE™ Phase IIIb/IV Clinical Trial Servicing
PAREXEL PACE™, supports clients with strategies and systems specifically developed for Phase IIIb studies. Our experience spans many therapeutic areas and ranges from single-country studies to those carried across multiple national boundaries and continents.